Clinical Trial Update: Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the immunogenicity and safety of a pentavalent DTPa-HBV-IPV/Hib vaccine given at 2, 3, and 4 months of age.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Disease
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTPa-HBV-IPV/Hib vaccine (DTPa-HBV-IPV/Hib vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Tetanus | Phase 2 | Status: COMPLETED